



---

## THIRD PARTY APPLICATION TO ADD THE COMPANY AS A PARTY TO LEGAL PROCEEDINGS

---

The Board of Directors (the "**Board**") of TalkMed Group Limited (the "**Company**") refers to its announcement on 15 February 2022 in relation to disposal of its entire 55.2% stake in Stem Med Pte. Ltd. ("**Stem Med**") to Edge Capital Fund SP2 Pte. Ltd. ("**ECF**") (the "**Divestment**").

Pursuant to the Divestment in October 2021, Stem Med and its subsidiaries, Stem Med Indonesia Pte. Ltd. and DrSG Cellular Wellness Pte. Ltd., ceased to be subsidiaries of the Company and the Company was no longer involved in the management of the aforementioned companies.

In September 2023, Stem Med commenced legal proceedings against, among others, its ex-directors who included Dr Ang Peng Tiam, Chief Executive Officer and Executive Director of the Company ("**Dr Ang**") and Dr Khoo Kei Siong, alternate director to Dr Ang.

The Board wishes to inform shareholders that ECF is seeking the permission from the Court to file an application to add the Company as a defendant to the legal proceedings.

The Company is seeking legal advice on this matter and will make further announcements to update its shareholders as and when there are any further material updates to this matter.

By Order of the Board

Lee Boon Yong  
Chief Financial Officer  
5 February 2024